Douglas Auld
Doug joined the Novartis Institutes of Biomedical Research (NIBR) in 2010. At NIBR, Doug’s lab provides assay development expertise and resources to support early-stage drug development efforts. Doug also manages a lab at NIBR that provides resources and expertise in high-throughput biology to support external collaborations and has worked with multiple academic institutes in this effort. Doug has expertise in assay development, biochemistry, enzymology, cell-based assay designs, and high content imaging. Doug is also a founding editor and contributor to the Assay Guidance Manual (AGM), an eBook available for free on the NCBI web site which aims to capture the tribal knowledge of the pharmaceutical industry so that others can learn from both successes and failures. (https://www.ncbi.nlm.nih.gov/books/NBK53196/).Doug has 20 years of experience in the drug discovery industry. He completed his Ph.D. at UNC with Prof. Gary J. Pielak in the Dept. of Chemistry in 1993 and did his post-doctoral training at MIT with Prof. Paul Schimmel studying tRNA synthetases (1994-1996). Following post-doctoral training, Doug decided to go to a fledging biotechnology company aimed at applying combinatorial chemistry to drug discovery. He joined Pharmacopeia at an early stage ( 150 scientists. In 2004, Doug was hired by the U.S. National Institute of Health to start the NIH Chemical Genomics Center (NCGC). At the NCGC he worked to establish a center of scientific excellence which has now become part of the National Center for Advancing Translational Sciences (1 of 27 Institutes and Centers at the NIH) with wide-reaching effects benefiting the improvement of human health as well as providing training to young scientists interested in biomedical research. At the NCGC his group was deeply involved in profiling the PubChem library against a wide-range of biochemical and cell-based assays and applied expertise in both biology and synthetic chemistry required to develop high quality chemical probes. This effort involved successfully mentoring both bachelor and Ph.D. level scientists in translational research. In 2006 Doug was awarded a U.S. National Institutes of Health Merit Award for “Outstanding leadership in establishing the NIH Chemical Genomics Center” presented by Francis S. Collins. See also his interview in Assays and Drug Development Technologies at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5116652/.
Abstracts this author is presenting: